Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriers.

IF 3 4区医学 Q2 CHEMISTRY, APPLIED

Journal of microencapsulation Pub Date : 2025-01-17 DOI:10.1080/02652048.2025.2451848

Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz

{"title":"Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriers.","authors":"Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz","doi":"10.1080/02652048.2025.2451848","DOIUrl":null,"url":null,"abstract":"This study evaluated albendazole (ABZ) nanostructured lipid carriers (NLCs) for hepatocellular carcinoma treatment. ABZ-NLCs were prepared using emulsification-ultrasonication and optimised using a Box-Behnken design. Independent variables-lipids concentration (X1), surfactant concentration (X2), and sonication duration (X3)-were assessed for their effect on mean diameter (Y1), PDI (Y2), and entrapment efficiency (Y3). The optimised formulation exhibited a mean diameter of 166.13 ± 3.72 nm, a PDI of 0.17 ± 0.01, a zeta potential of -39.86 ± 1.84 mV, an entrapment efficiency of 94.25 ± 6.12%, and a loading capacity of 99.93 ± 7.15 mg/g. Following chitosan coating (ABZ-CS-NLCs), all parameters were maintained, and the zeta potential developed to +24.61 ± 1.32 mV, improving cellular interaction. The cytotoxicity assays revealed that ABZ-CS-NLCs were more effective than uncoated NLCs and free ABZ, with an IC50 value of 8.89 μM in HepG2 cells. Overall, ABZ-CS-NLCs demonstrate a promising and effective delivery platform for targeted hepatic cancer therapy.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"1-16"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of microencapsulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02652048.2025.2451848","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}

引用次数: 0

Abstract

This study evaluated albendazole (ABZ) nanostructured lipid carriers (NLCs) for hepatocellular carcinoma treatment. ABZ-NLCs were prepared using emulsification-ultrasonication and optimised using a Box-Behnken design. Independent variables-lipids concentration (X₁), surfactant concentration (X₂), and sonication duration (X₃)-were assessed for their effect on mean diameter (Y₁), PDI (Y₂), and entrapment efficiency (Y₃). The optimised formulation exhibited a mean diameter of 166.13 ± 3.72 nm, a PDI of 0.17 ± 0.01, a zeta potential of -39.86 ± 1.84 mV, an entrapment efficiency of 94.25 ± 6.12%, and a loading capacity of 99.93 ± 7.15 mg/g. Following chitosan coating (ABZ-CS-NLCs), all parameters were maintained, and the zeta potential developed to +24.61 ± 1.32 mV, improving cellular interaction. The cytotoxicity assays revealed that ABZ-CS-NLCs were more effective than uncoated NLCs and free ABZ, with an IC50 value of 8.89 μM in HepG2 cells. Overall, ABZ-CS-NLCs demonstrate a promising and effective delivery platform for targeted hepatic cancer therapy.

查看原文本刊更多论文

利用表面修饰的纳米结构脂质载体优化阿苯达唑在肝细胞癌（HepG2细胞）中的递送和抗癌潜力评估。

本研究评估了阿苯达唑（ABZ）纳米结构脂质载体（NLCs）治疗肝细胞癌的效果。采用乳化超声法制备ABZ-NLCs，并采用Box-Behnken设计对其进行优化。独立变量——脂质浓度（X1）、表面活性剂浓度（X2）和超声时间（X3）——被评估它们对平均直径（Y1）、PDI （Y2）和包封效率（Y3）的影响。优化后的配方平均粒径为166.13±3.72 nm， PDI为0.17±0.01，zeta电位为-39.86±1.84 mV，包封效率为94.25±6.12%，载药量为99.93±7.15 mg/g。壳聚糖包覆（ABZ-CS-NLCs）后，各参数保持不变，zeta电位达到+24.61±1.32 mV，细胞相互作用增强。细胞毒性实验表明，ABZ- cs -NLCs对HepG2细胞的IC50值为8.89 μM，优于未包被的NLCs和游离ABZ。总之，ABZ-CS-NLCs为肝癌靶向治疗提供了一个有前景且有效的给药平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of microencapsulation 工程技术-工程：化工

CiteScore

6.30

自引率

2.60%

发文量

审稿时长

3 months

期刊介绍： The Journal of Microencapsulation is a well-established, peer-reviewed journal dedicated to the publication of original research findings related to the preparation, properties and uses of individually encapsulated novel small particles, as well as significant improvements to tried-and-tested techniques relevant to micro and nano particles and their use in a wide variety of industrial, engineering, pharmaceutical, biotechnology and research applications. Its scope extends beyond conventional microcapsules to all other small particulate systems such as self assembling structures that involve preparative manipulation. The journal covers: Chemistry of encapsulation materials Physics of release through the capsule wall and/or desorption from carrier Techniques of preparation, content and storage Many uses to which microcapsules are put.